1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare Co., Ltd.

TTPEX:4194
6.50
TWD
-0.60
(-8.45%)
1.05BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.02
2.25
2.35
2.27
2.28
2.53
2.43
2.02
1.97
2.25
1.73
0.84
- -
- -
Basic EPS, GAAP
-3.05
-3.07
-3.25
-3.76
-2.99
-2.56
-2.26
-1.17
-1.65
-1.27
-2.12
-1.29
-0.76
- -
Free Cash Flow per Basic Share
-4.86
-1.75
-2.74
-3.57
-2.82
-2.28
-2.4
-0.93
-1.29
-1.23
-2.06
-1.02
-0.8
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
13.08
9.93
6.76
6.42
3.41
4.48
5.24
4.1
2.4
4.21
0.67
2.01
1.25
0.85
Tangible Book Value per Share
12.54
9.46
6.31
6.08
3.13
4.29
5.12
4.01
2.33
4.16
0.67
2.01
1.25
0.85
Basic Weighted Avg Shares
45
55
55
59
61
68
84
110
110
120
137
142
146
146
Sales/Revenue/Turnover
91
123
129
133
139
173
204
222
217
270
237
119
- -
- -
Operating Margin (%)
-144.4
-147.53
-144.04
-161.31
-133.96
-98.92
-91.63
-59.22
-78.22
-55.49
-121.7
-159.82
- -
- -
Depreciation Expense
13
19
20
20
19
18
22
19
18
17
17
12
12
- -
Net Income, GAAP
-137
-168
-177
-220
-181
-175
-191
-129
-181
-153
-289
-183
-111
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-151.13
-136.37
-138.01
-165.52
-130.71
-100.96
-93.36
-58.1
-83.52
-56.59
-122.15
-154.5
- -
- -
Working Capital
586
396
229
271
104
268
486
376
189
456
31
245
134
77
LT Debt
- -
- -
- -
- -
- -
- -
25
22
19
18
13
10
6
6
Total Equity
746
543
369
392
209
356
576
451
264
523
83
294
183
125
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-26.7
-38.89
-57.74
-60.33
-61.77
-40.88
-25.07
-50.69
-38.88
-95.48
-97.23
-46.69
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
9
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
146
146
146
Market Capitalization
896
1,124
1,045

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
227
165
97
Cash, Cash Equivalents & STI
207
144
79
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
31
20
Payables & Accruals
- -
- -
- -
ST Debt
5
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.76%
37.47%
-37.82%
Free Cash Flow
5.78%
13.08%
-19.58%
Net Income, GAAP
1.79%
7.69%
-39.32%
Sales/Revenue/Turnover
-8.07%
-27.95%
-100%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
119
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.29
2025
- -
- -
-0.76
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ching Hua Yang
Full Time Employees
45
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 88, Neihu Rd. Taipei TPE Taiwan 11493
IPO Date
Dec 13, 2013
Website
hshc.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Holy Stone Healthcare Co., Ltd. (4194.TWO) develops, manufactures and markets hyaluronic acid-based therapeutics and medical devices for orthopedic, gastrointestinal and oncological applications; its core products include RenehaVis for knee osteoarthritis pain relief, SportVis for tendon and ligament injury recovery, TRUD for ulcerative colitis treatment, GAF for anal fissure healing, and pipeline candidates such as IBD98-M (hyaluronic acid-mesalamine oral capsules in Phase II for inflammatory bowel disease), CA102N (hyaluronic acid-nimesulide conjugate in Phase II preparation for metastatic colorectal cancer and pancreatic cancer via orphan drug designation pursuit) and ND108E for Alzheimer's disease. Founded in January 2001 and headquartered in Taipei, Taiwan at 4F, No. 88, Sec. 1, Neihu Rd., Neihu Dist., the company operates as a subsidiary of Holy Stone Enterprise Co., Ltd. (3026.TWO) with subsidiaries including Holy Stone Biotech in Norwich, UK for European R&D and MDT International in Geneva, Switzerland for sales and marketing; it maintains a PIC/s GMP-qualified pilot plant in Hsinchu Biomedical Science Park, Taiwan, and conducts global clinical collaborations. Geographically, it serves markets in Taiwan, Europe and pursues international expansion through CE-marked products and FDA submissions. Recent developments encompass submission of an IND application to the US FDA for CA102N Phase II trials in metastatic colorectal cancer, approval for Phase II trials of IBD98-M by China's NMPA in 2023, presentation of preclinical CA102N data at the 2024 AACR annual meeting demonstrating pancreatic cancer efficacy, publication of ND108E Alzheimer's data in 2023, winning the 2025 Taipei Biotech Innovation Award, and a corporate split-off in 2023-2024 transferring agency distribution and European private-label businesses to newly formed Holy Young BioMedical Co., Ltd. to sharpen focus on new drug R&D.